Genomics Core

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5U19AI168631-03

Grant search

Key facts

  • Disease

    COVID-19, Dengue
  • Start & end year

    2022
    2027
  • Known Financial Commitments (USD)

    $300,064
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Robert Sebra
  • Research Location

    United States of America
  • Lead Research Institution

    ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

GENOMICS CORE D PI: Dr. Sebra PROJECT SUMMARY Recent advances in genomics technology and associated data analysis methods have provided a framework to interrogate the human host response to vaccination and the dynamic interplay between host and pathogen during viral infection at an unprecedented resolution. The integration of molecular and cellular data alongside clinical metadata and serologic data nucleates the potential to identify signatures of viral immunity outcomes by characterizing changes in innate immunity before and after vaccination. However, no single technology is sufficient to address the multitude of open questions raised by deep molecular immune profiling, necessitating an integrated approach for profiling immunity and vaccine response. Analysis of PBMCs and histocultures across VIVA projects with a variety of cutting-edge and custom high throughput, molecular and high-resolution multi-omics technologies will provide the best database for vaccine immune responses across these systems. The VIVA Genomics Core D aims to leverage a data generation technology suite inclusive of bulk RNAseq, serologic data, single cell CITEseq, CyTOF, spatial transcriptomics, viral genomics and multi-scale computational approaches for the comprehensive characterization of immune response to predict vaccine outcomes. Using the integration of these data, Core D will deliver multi-omics data generation and quality control for seamless analysis, integration and annotation with the Genomics Data Analysis and Management Core E across VIVA projects including the Immune/Clinical Core, Project 1 (SARS-CoV-2), Project 2 (seasonal influenza), Project 3 (tetravalent DENV). Core D will serve as an invaluable resource for the VIVA HIPC team coupling molecular data generation and Core E data driven approaches to foster technology refinement and development and promote collaboration between VIVA projects.